Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.60 |
| ▸ | MMP2 | P08253 | 9/20 | 0.55 |
| ▸ | MMP9 | P14780 | 7/20 | 0.55 |
| ▸ | MMP3 | P08254 | 3/20 | 0.55 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 9/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MMP14 | P50281 | 3/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6782627 | 0.90 | MMP2 (0.56) | ADAMTS4MMP2MMP9MMP3ADAM10 | |
| SCHEMBL12152323 | 0.89 | MMP2 (0.61) | ADAMTS4MMP2MMP9MMP3ADAM10 | |
| SCHEMBL4808185 | 0.87 | ADAMTS4 (0.63) | ADAMTS4MMP2MMP9MMP3ADAM10 | |
| SCHEMBL6783061 | 0.85 | MMP2 (0.45) | ADAMTS4MMP2MMP9MMP3ADAM10 | |
| SCHEMBL6785924 | 0.83 | MMP2 (0.52) | ADAMTS4MMP2MMP9MMP3ADAM10 | |
| SCHEMBL6787148 | 0.82 | MMP2 (0.51) | ADAMTS4MMP2MMP9MMP3ADAM10 | |
| SCHEMBL6787212 | 0.81 | MMP2 (0.51) | ADAMTS4MMP2MMP9MMP3ADAM10 | |
| SCHEMBL7248756 | 0.79 | MMP2 (0.52) | ADAMTS4MMP2MMP9MMP3ADAM10 | |
| SCHEMBL4806731 | 0.79 | ADAMTS4 (0.53) | ADAMTS4MMP2MMP9MMP3ADAM10 | |
| SCHEMBL6782185 | 0.78 | ADAMTS4 (0.49) | ADAMTS4MMP2MMP9MMP3ADAM10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| EP-1109787-B1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | MMP13, MMP25, MMP3 | ADAMTS4 38/4885MMP2 6/4885MMP9 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.